Sorafenib in the treatment of metastatic renal cell cancer

Jakub Żołnierek

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

7/2008
vol. 12

Send email

Copy url:

abstract:

Sorafenib in the treatment of metastatic renal cell cancer

Jakub Żołnierek

Współczesna Onkologia (2008) vol. 12; 7 (314–317)

Online publish date: 2008/11/03

View full text Get citation

Renal cell carcinoma appears to be resistant to conventional treatment modalities. Introduction of advanced techniques of molecular biology into practice helped to establish the potent role of membrane receptors for growth factors, especially the component with activity of thyrosine kinases, in growth, proliferation, invasion and formation of metastatic lesions. One of the most investigated and advanced agents in clinical trials is sorafenib (Nexavar). The article is a short review of literature regarding the drug with special attention paid to clinical data.

keywords:

Sorafenib in the treatment of metastatic renal cell cancer

Jakub Żołnierek

renal cell carcinoma, sorafenib tosylate, metastasis